Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Overview of attention for article published in European Urology, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 5 news outlets
twitter: 58 X users
facebook: 1 Facebook page

googleplus: 1 Google+ user
guideline: 2 clinical guideline sources

Readers on

mendeley: 168 Mendeley

So far, Altmetric has seen 6 news stories from 5 outlets.

Determining the Optimal Use of Adjuvant Immunotherapy in Renal Cell Carcinoma

OncLive, 19 Jun 2023

Benjamin Garmezy, MD Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and…

‘Dawn of a new era’ in the treatment of renal cell carcinoma

Pediatric News , 07 Sep 2021

The decades-long search for a safe, effective adjuvant therapy for patients with resected kidney cancer at high risk of…

'Dawn of a New Era' in the Treatment of Renal Cell Carcinoma

Medscape, 18 Aug 2021

The decades-long search for a safe, effective adjuvant therapy for patients with resected kidney cancer at high risk of…

Ca renale, sunitinib adiuvante non allunga la vita, ma riduce le recidive a distanza

Pharmastar Italy, 19 Oct 2017

In pazienti affetti da carcinoma a cellule renali, il trattamento adiuvante con l’inibitore delle tirosin chinasi (TKI…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.